PBAC's latest decision on Delgocitinib: Recommended with restriction (2025). Considered for Treatment of moderate to severe chronic hand eczema (CHE) in adults who have had an inadequate response to, or for whom topical corticosteroids are not advisable.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
—
ICER not stated
Submissions
1
first 2025
Submissions
1
2025 → 2025
Eligible population
Adults (aged ≥18 years) with moderate to severe chronic hand eczema who have had an inadequate response to, or for whom topical corticosteroids are not advisable.
Therapy area
Dermatology
Line of therapy
Second-line
Evidence base
RCT
Primary endpoint
IGA-CHE TS at Week 16
Key trials
DELTA 1, DELTA 2, DELTA 3, LIBERTY-AD-HAFT
Comparator
Standard of care (non-medicated emollient use alone; avoidance of known irritants and allergens)
Economic model
CUA
ICER note
ICER value not stated in the public summary document provided. The economic evaluation section appears to be incomplete in the extracted text.